Literature DB >> 12877907

Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.

Giovanni Anfossi1, Isabella Russo, Paola Massucco, Luigi Mattiello, Mariella Trovati.   

Abstract

INTRODUCTION: We investigated whether the platelets from obese subjects are sensitive as those from controls to the antiaggregating effects of N-acetyl-L-cysteine (NAC)-an antioxidant thiol that increases availability of endogenous nitric oxide (NO)-and of superoxide dismutase (SOD) and amifostine which act as scavengers of superoxide anion.
MATERIALS AND METHODS: In platelets from obese subjects (n=20, body mass index [BMI]=34.2+/-1.9 kg/m(2), homeostasis model assessment [HOMA] index=5.5+/-1.1) and controls (n=20, BMI=21.4+/-0.6 kg/m(2), HOMA index=1.4+/-0.2), we investigated the effects of NAC on aggregation and on 3',5'-cyclic guanosine monophosphate (cGMP) synthesis and the interplay between NAC and the organic nitrates glyceryl trinitrate (GTN) and sodium nitroprusside (SNP). Similar experiments were carried out with SOD and amifostine.
RESULTS: We found that a 3-min platelet exposure to NAC decreased aggregation and increased cGMP in controls, but not in obese subjects. Only more prolonged incubations exerted a small effect also in obese subjects. GTN and SNP increased platelet cGMP in both groups, but their effect was much lower in obese subjects. NAC (3 mmol/l), SOD (150 U/ml), and amifostine (50 micromol/l) enhanced the increase of cGMP elicited by NO donors, but again, the effect was much lower in obese subjects.
CONCLUSIONS: Since antioxidants do not restore the effects of NO in platelets from obese subjects, we hypothesize that oxidative stress is not the unique cause of platelet resistance to NO in obesity and suggest that a resistance to the NO action at the guanylate cyclase level could play a role in this phenomenon, potentially involved in the increased atherothrombotic risk linked to obesity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877907     DOI: 10.1016/s0049-3848(03)00284-6

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease.

Authors:  Victor L Serebruany; Alex Malinin; Stephen Ong; Dan Atar
Journal:  J Thromb Thrombolysis       Date:  2007-05-26       Impact factor: 2.300

2.  N-Acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial.

Authors:  A T Treweeke; T J Winterburn; I Mackenzie; F Barrett; C Barr; G F Rushworth; I Dransfield; S M MacRury; I L Megson
Journal:  Diabetologia       Date:  2012-08-31       Impact factor: 10.122

3.  Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes.

Authors:  Kyle R Gibson; Tim J Winterburn; Fiona Barrett; Sushma Sharma; Sandra M MacRury; Ian L Megson
Journal:  Cardiovasc Diabetol       Date:  2011-05-21       Impact factor: 9.951

Review 4.  ROS in Platelet Biology: Functional Aspects and Methodological Insights.

Authors:  Elena Masselli; Giulia Pozzi; Mauro Vaccarezza; Prisco Mirandola; Daniela Galli; Marco Vitale; Cecilia Carubbi; Giuliana Gobbi
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

Review 5.  Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.

Authors:  Yuliy Y Chirkov; Thanh H Nguyen; John D Horowitz
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

6.  High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.

Authors:  Isabella Russo; Michela Viretto; Cristina Barale; Luigi Mattiello; Gabriella Doronzo; Andrea Pagliarino; Franco Cavalot; Mariella Trovati; Giovanni Anfossi
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461

Review 7.  Preventing the development of severe COVID-19 by modifying immunothrombosis.

Authors:  Gerwyn Morris; Chiara C Bortolasci; Basant K Puri; Lisa Olive; Wolfgang Marx; Adrienne O'Neil; Eugene Athan; Andre Carvalho; Michael Maes; Ken Walder; Michael Berk
Journal:  Life Sci       Date:  2020-10-20       Impact factor: 5.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.